Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

161. Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization (Full text)

Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization Pulmonary congestion remains a diagnostic challenge in patients with heart failure (HF). The recommended method, chest X-ray (CXR), lacks in accuracy, whereas quantitative tomographic lung scintigraphy [ventilation/perfusion single-photon emission computed tomography (V/P SPECT)] has shown promising results but needs independent validation. The aim of this study (...) congestion in the clinical setting.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure PubMed

162. Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment (Full text)

Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment Left atrium (LA) dilation is associated with adverse cardiovascular (CV) outcomes. Blood stasis, thrombus formation and atrial fibrillation may occur, especially in heart failure (HF) patients. It is not known whether preventive antithrombotic treatment may decrease the incidence of CV events in HF patients with LA enlargement. We investigated the relationship between LA enlargement (...) .© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure PubMed

163. Identifying cut‐off scores for interpretation of the Heart Failure Impact Questionnaire (Full text)

Identifying cut‐off scores for interpretation of the Heart Failure Impact Questionnaire Heart failure (HF) influences health-related quality of life. However, the factors that contribute to health-related quality of life remain unclear in Taiwan. We aim to identify the factors influencing health-related quality of life in HF patients.Hospitalized HF (N = 225) patients were included from April 2011 to April 2014. Health-related quality of life was assessed by using the 36-Item Short-Form (...) Health Survey (SF-36) and the Minnesota Living with Heart Failure Questionnaire. A new cut-off was conducted based on the combination of SF-36 and Minnesota Living with Heart Failure questionnaire.There were significant differences between good and poor quality groups on age, gender, education levels, occupational classification caregiver, New York Heart Association classes, and the numbers of comorbidities. The logistic regression analysis showed that the number of comorbidities was more than three

2018 Nursing open PubMed

164. Commentary: MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure (Full text)

Commentary: MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure 30062098 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Commentary: MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. 95 10.3389/fcvm.2018.00095 Schmitz Boris B Institute of Sports Medicine, Molecular Genetics of Cardiovascular Disease, University Hospital Muenster, Muenster, Germany. Brand Stefan (...) -Martin SM Institute of Sports Medicine, Molecular Genetics of Cardiovascular Disease, University Hospital Muenster, Muenster, Germany. eng Journal Article Comment 2018 07 16 Switzerland Front Cardiovasc Med 101653388 2297-055X Hypertension. 2018 Feb;71(2):280-288 29255073 cardiac hypertrophy exercise heart failure micoRNAs remodeling 2018 06 11 2018 06 28 2018 8 1 6 0 2018 8 1 6 0 2018 8 1 6 1 epublish 30062098 10.3389/fcvm.2018.00095 PMC6054969 J Mol Cell Cardiol. 2007 Jun;42(6):1137-41 17498736

2018 Frontiers in cardiovascular medicine PubMed

165. Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial (Full text)

Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial In patients with heart failure and a pathologically prolonged PR interval, left ventricular (LV) filling can be improved by shortening atrioventricular delay using His-bundle pacing. His-bundle pacing delivers physiological ventricular activation and has been shown to improve acute haemodynamic function in this group of patients. In the HOPE-HF (His Optimized Pacing Evaluated (...) for Heart Failure) trial, we are investigating whether these acute haemodynamic improvements translate into improvements in exercise capacity and heart failure symptoms.This multicentre, double-blind, randomized, crossover study aims to randomize 160 patients with PR prolongation (≥200 ms), LV impairment (EF ≤ 40%), and either narrow QRS (≤140 ms) or right bundle branch block. All patients receive a cardiac device with leads positioned in the right atrium and the His bundle. Eligible patients also

2018 ESC heart failure PubMed

166. Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure (Full text)

Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well-known inhibitor of AVP secretion) in HF is unknown.We (...) studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme-linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83-1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6-0.77 pg/mL; P = 0.0002). Heart failure

2018 ESC heart failure PubMed

167. Low frequency electrical muscle stimulation and endothelial function in advanced heart failure patients (Full text)

Low frequency electrical muscle stimulation and endothelial function in advanced heart failure patients Obtain initial estimates of the change in brachial artery endothelial function and maximal oxygen uptake (VO2peak ) with 8 weeks of low-frequency electrical muscle stimulation (LF-EMS) or sham in patients with advanced chronic heart failure.Using a double blind, randomized design, 35 patients with chronic heart failure (New York Heart Association class III-IV) were assigned to 8 weeks (5 × 60 (...) . FMD improved by 2.56% (95% confidence interval: 0.69 to 3.80) with LF-EMS compared with sham (P = 0.07). There were no notable changes in VO2peak .Improvements in FMD with LF-EMS may have a clinically meaningful effect as higher FMD is associated with better prognosis. This is a preliminary finding, and a larger trial is warranted.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure PubMed

168. Heart failure

Heart failure Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

169. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. (Full text)

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction. There is uncertainty whether these treatments are beneficial for people with heart failure with preserved ejection fraction and a comprehensive review of the evidence (...) is required.To assess the effects of beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and mineralocorticoid receptor antagonists in people with heart failure with preserved ejection fraction.We searched CENTRAL, MEDLINE, Embase and two clinical trial registries on 25 July 2017 to identify eligible studies. Reference lists from primary studies and review articles were checked for additional studies. There were no language

2018 Cochrane PubMed

170. A novel cardiac output response to stress test developed to improve diagnosis and monitoring of heart failure in primary care (Full text)

A novel cardiac output response to stress test developed to improve diagnosis and monitoring of heart failure in primary care Primary care physicians lack access to an objective cardiac function test. This study for the first time describes a novel cardiac output response to stress (CORS) test developed to improve diagnosis and monitoring of heart failure in primary care and investigates its reproducibility.Prospective observational study recruited 32 consecutive primary care patients (age, 63 (...) Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure PubMed

171. Eligibility for cardiac resynchronization therapy in patients hospitalized with heart failure (Full text)

Eligibility for cardiac resynchronization therapy in patients hospitalized with heart failure Recent guidelines recommend cardiac resynchronization therapy (CRT) in mildly symptomatic heart failure (HF) but favour left bundle branch block (LBBB) morphology in patients with moderate QRS prolongation (120-150 ms). We defined how many patients hospitalized with HF fulfil these criteria.A single-centre retrospective cohort study of 363 consecutive patients hospitalized with HF (438 admissions (...) patients hospitalized with HF fulfil LVEF and QRS criteria for CRT, most having a Class I or IIa indication. However, a large proportion is ineligible owing to co-morbidities or requires medical optimization. Although uptake of CRT was reasonable, there remain opportunities for improvement.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure PubMed

172. Prospective evaluation of integrated device diagnostics for heart failure management: results of the TRIAGE‐HF study (Full text)

Prospective evaluation of integrated device diagnostics for heart failure management: results of the TRIAGE‐HF study The primary aim of the TRIAGE-HF trial was to correlate cardiac implantable electronic device-generated heart failure risk status (HFRS) with signs, symptoms, and patient behaviours classically associated with worsening heart failure (HF).TRIAGE-HF enrolled 100 subjects with systolic HF implanted with a Medtronic high-performance device and followed up at three Canadian HF (...) data on the distribution of abnormal device parameters contributing to high HFRS. High HFRS has good predictive accuracy for patient-reported signs, symptoms, and behaviours associated with worsening HF status. As such, HFRS may be a useful tool for ambulatory HF monitoring to improve both patient-centred and health system level outcomes.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure PubMed

173. Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence (Full text)

Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence Globally, acute heart failure (AHF) remains an ongoing public health issue with its prevalence and mortality increasing in the east and the west. Effective treatment strategies to stabilize AHF are important to alleviate clinical symptoms and to improve clinical outcomes. However, despite the progress in the management of stable and chronic heart failure, no single agent has been proven (...) to play a definitive role in the management of AHF. As a consequence, contemporary treatment strategies for patients with AHF vary greatly by region. This manuscript reviews the medical treatment options for AHF, with an emphasis on the differences between the treatment strategies in the USA and Japan. This information would provide a framework for clinicians to evaluate and manage patients with AHF and highlight the remaining questions to improve clinical outcomes.© 2018 The Authors. ESC Heart

2018 ESC heart failure PubMed

174. Sex, drugs, and heart failure: a sex‐sensitive review of the evidence base behind current heart failure clinical guidelines (Full text)

Sex, drugs, and heart failure: a sex‐sensitive review of the evidence base behind current heart failure clinical guidelines Heart failure (HF) is a complex disease, almost as common in women as in men. Nonetheless, HF clinical presentation, prognosis, and aetiology vary by sex. This review summarizes the current state of sex-sensitive issues related to HF drugs included in treatment guidelines and suggests future directions for improved care. Heart failure presentation differs between female (...) , such as torsade de pointes and angiotensin-converting enzyme inhibitor-induced cough, occur more frequently in women, we emphasize the need to test medications thoroughly in both sexes and explore sexual dimorphisms. To better represent all of the targeted patient population and provide better care for all, two kinds of change must come about: recruitment methods to randomized clinical trial samples need to evolve and the participation needs to seem more attractive to women.© 2018 The Authors. ESC Heart

2018 ESC heart failure PubMed

175. Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism (Full text)

Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism Recent advances in cancer cell metabolism provide unprecedented opportunities for a new understanding of heart metabolism and may offer new approaches for the treatment of heart failure. Key questions driving the cancer field to understand how tumor cells reprogram metabolism and to benefit tumorigenesis are also applicable to the heart. Recent experimental and conceptual advances in cancer cell

2018 Frontiers in cardiovascular medicine PubMed

176. Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure (Full text)

Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure The aim of this study was to identify echocardiographic predictors of improved or worsening renal function during intravenous diuresis for decompensated heart failure. Secondary aim included defining the incidence and clinical risk factors for acute changes in renal function with decongestion.A retrospective review of 363 patients admitted to a single centre for decompensated heart (...) admitted with decompensated heart failure. WRF was statistically more likely in patients with a preserved left ventricular ejection fraction. A trend towards IRF was noted in patients with global right ventricular dysfunction.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure PubMed

177. Prospective assessment of combined handgrip strength and Mini‐Cog identifies hospitalized heart failure patients at increased post‐hospitalization risk (Full text)

Prospective assessment of combined handgrip strength and Mini‐Cog identifies hospitalized heart failure patients at increased post‐hospitalization risk The utility of combined assessment of both frailty and cognitive impairment in hospitalized heart failure (HF) patients for incremental post-discharge risk stratification, using handgrip strength and Mini-Cog as feasible representative parameters, was investigated.A prospective, single-centre cohort study of older adults (age ≥65 (...) impaired according to severely reduced Mini-Cog performance show the worst midterm post-discharge outcomes after HF hospitalization.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure PubMed

178. Daily non‐invasive haemodynamic telemonitoring for efficacy evaluation of MitraClip® implantation in patients with advanced systolic heart failure (Full text)

Daily non‐invasive haemodynamic telemonitoring for efficacy evaluation of MitraClip® implantation in patients with advanced systolic heart failure Patients with advanced systolic chronic heart failure frequently suffer from progressive functional mitral regurgitation. We report our initial experience in patients with an implanted pulmonary artery pressure (PAP) sensor, who developed severe mitral regurgitation, which was treated with the MitraClip system. We non-invasively compared changes (...) in PAP values in patients after MitraClip with PAP changes in patients without MitraClip.Among 28 patients with New York Heart Association III heart failure with implanted PAP sensor for haemodynamic telemonitoring from a single centre, four patients (age 66 ± 6 years, left ventricular ejection fraction 21 ± 3%, and cardiac index 1.8 ± 0.3) received a MitraClip procedure and were compared with 24 patients (age 72 ± 8 years, left ventricular ejection fraction 26 ± 9.9%, and cardiac index 2.0 ± 1.0

2018 ESC heart failure PubMed

179. Heart Failure. (PubMed)

Heart Failure. Heart failure affects more than 6 million people in the United States and incurs a heavy toll in morbidity, mortality, and health care costs. It frequently coexists with other important disorders, including hypertension, coronary artery disease, diabetes, and obesity. Decades of clinical trials have shown that several medications and interventions are effective for improving outcomes; however, mortality and hospitalization rates remain high. More recently, additional medications (...) and devices have shown promise in reducing the health burden of heart failure.

2018 Annals of Internal Medicine

180. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association (Full text)

Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January (...) 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association , MD, Chair , MD, MS, FAHA, Co-Chair , MD , MD, PhD, FAHA , MD , MD , MD, MS , MD, MPH, FAHA , MD , MD, PhD, FAHA , and MD, FAHA MDOn behalf of the American Heart Association Council on Clinical Cardiology; Council

2018 American Heart Association PubMed